Tests brain stimulation with language therapy for progressive aphasia
Tests mild electrical brain stimulation plus speech therapy in people with progressive aphasia.
Plain-language title generated from the registry record
Registry title: Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT05386394, who can take part
Where in Canada
- Baycrest Centre for Geriatric CareToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT05386394
- Record updated
- 5 May 2026
- Original description
While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.Read full original descriptionShow less
Phase II Clinical Trial of Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia
While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate the devastating impact of aphasia on patients' family, work, and social lives. Given that tDCS is inexpensive, easy to use (it is potentially amenable to home use by patients and caregivers), minimally invasive, and safe there is great promise to advance this intervention toward clinical use. The principal reason that tDCS has not found wide clinical application yet is that its efficacy has not been tested in large, multi-center, clinical trials. In this study, scientists in the three sites that have conducted tDCS clinical trials in North America-Johns Hopkins University and the University of Pennsylvania in the US, and the University of Toronto in Canada, will collaborate to conduct a multi-site, Phase II clinical trial of tDCS a population in dire need of better treatments.
Inclusion: Presence of aphasia attributable to non-fluent PPA or logopenic PPA; High school education (or more); Between the ages of 50 and 90; Must be able to understand the nature of the study and give informed consent.
Exclusion: Current abuse of alcohol or drugs, prescription or otherwise; Participant in another drug, device, or biologics trial within 30 days prior to enrollment; Subjects with metallic objects in the face or head other than dental apparatus, such as braces, fillings, or implants; Subjects with previous craniotomy or any breach in the skull; Exclusion for MRI, specifically:; Cognitive impairment of sufficient severity to preclude giving informed consent (Mini Mental State Examination [MMSE] less than 15); Any unrelated neurologic or physical condition that impairs communication ability; History of unrelated neurological conditions, including but not limited to traumatic brain injury (TBI), stroke, or small vessel disease, that has resulted in a neurologic deficit; Any additional neurological condition that would likely reduce the safety of study participation, including central nervous system (CNS) vasculitis, intracranial tumor, intracranial aneurysm, multiple sclerosis, or arteriovenous malformations; A medically unstable cardiopulmonary or metabolic disorder; Individuals with pacemakers or implantable cardiac defibrillators; Terminal illness associated with survival of less than 12 months; Major active psychiatric illness that may interfere with required study procedures or treatments, as determined by the enrolling physician; History of spontaneous or partial complex seizures or unexplained loss of consciousness within 6 months of enrollment; Presence of any of the following devices: cardiac pacemaker, other pacemakers (for carotid sinus, insulin pumps, nerve stimulators, lead wires or similar wires), optic implant, implanted cardiac defibrillator, aneurysm clip, any electronically/magnetically/mechanically activated implant, ferromagnetic implants (coils, filters, stents; metal sutures or staples); Nursing a child, pregnant, or intending to become pregnant during the study; Left-handedness; Exclusion for tDCS, specifically:; Presence of any of the following: pregnancy, claustrophobia, metal in eye or orbit, tattooed eyeliner.